دورية أكاديمية
Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study
| العنوان: | Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study |
|---|---|
| المؤلفون: | Escudero-Sanchez, Rosa, Muriel García, Alfonso, García Fernández, Sergio, Valencia Alijo, Angela, Tasias Pitarch, Mariona, Merino De Lucas, Esperanza, Gutierrez Rojas, Angela, Ramos Martínez, Antonio, Salavert Lletí, Miguel, Giner, Livia, Ruíz Ruigomez, María, García Basas, Lorena, Fernández Fradejas, Jorge, Olmedo Sampedrio, María, Cano Yuste, Angela, Díaz Pollán, Beatriz, Rodríguez Hernández, María Jesús, Martín Segarra, Oriol, Sáez Bejar, Carmen, Armiñanzas Castillo, Carlos, Gutiérrez, Belén, Rodríguez-Pardo, Dolors, De La Torre Cisneros, Julián, López Medrano, Francisco, Cobo Reinoso, Javier |
| المساهمون: | Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades |
| المصدر: | Journal of Antimicrobial Chemotherapy ; volume 77, issue 7, page 1996-2002 ; ISSN 0305-7453 1460-2091 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Infectious Diseases, Pharmacology (medical), Pharmacology, Microbiology (medical) |
| الوصف: | Background Both fidaxomicin and bezlotoxumab (used in combination with an antibiotic against Clostridioides difficile) achieve reductions in recurrence rates of C. difficile infection (CDI). However, the two strategies have never been compared. Methods Data from two retrospective cohorts of ‘real-life’ use of fidaxomicin and bezlotoxumab in combination with a standard anti-C. difficile antibiotic were used to compare the rates of recurrence of both strategies. Since the two cohorts were not identical, we used a propensity score analysis. Results Three hundred and two patients were included: 244 in the fidaxomicin cohort and 78 in the bezlotoxumab cohort. A history of renal failure or immunosuppression was more frequent in patients receiving bezlotoxumab (39.7% and 66.7% versus 26.6% and 38.9%; P = 0.03 and P < 0.001, respectively), but the severity and number of previous CDI episodes were similar in both cohorts. We observed that 19.3% of the patients in the fidaxomicin cohort experienced recurrence, compared with 14.1% in the bezlotoxumab cohort (OR 1.45; 95% CI 0.71–2.96; P = 0.29) but the difference remained non-significant after propensity score matching using previously defined variables (OR 1.24; 95% CI 0.50–3.07; P = 0.64). Moreover, the multivariate analysis did not show differences depending on the drug used. Conclusions We observed that fidaxomicin and bezlotoxumab are prescribed in similar clinical scenarios, although those treated with bezlotoxumab have greater comorbidity. The proportion of recurrences was numerically lower in those treated with bezlotoxumab, although the propensity analysis did not find significant differences between the two drugs. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/jac/dkac106 |
| الإتاحة: | https://doi.org/10.1093/jac/dkac106Test https://academic.oup.com/jac/article-pdf/77/7/1996/44373508/dkac106.pdfTest |
| حقوق: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelTest |
| رقم الانضمام: | edsbas.9785FF57 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/jac/dkac106 |
|---|